Study of the safety and effectiveness of drug AZD4017 at reducing pressure in the brain, in idiopathic intracranial hypertension.

Registry ID

EUCTR2013-003643-31

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

University of Birmingham

Start date

2014-01-22

Completion date

2016-12-19

Last update

2026-08-16

Conditions

• Idiopathic Intracranial Hypertension

Summary

The primary objective of this study is to evaluate whether 12 weeks of a 11β-hydroxysteroid dehydrogenase inhibitor (AZD4017) is effective and safe for reducing the raised intracranial pressure (pressure of fluid around the brain) observed in patients with idiopathic intracranial hypertension, compared to a placebo ('dummy' drug with no active properties).

Locations

• , , UK

Related clinical trials

• Disease Biosignatures in ALS/FTD Spectrum: New Impactful Biological Perspectives Beyond Clinical Approaches
• Prospective Ocular Imaging for Intracranial Pressure Evaluation
• Ocular Perfusion in Patients With Idiopathic Intracranial Hypertension

View on source registry